1. Home
  2. KOPN vs ACOG Comparison

KOPN vs ACOG Comparison

Compare KOPN & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kopin Corporation

KOPN

Kopin Corporation

HOLD

Current Price

$2.73

Market Cap

424.9M

Sector

Technology

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$6.18

Market Cap

115.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOPN
ACOG
Founded
1984
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Semiconductors
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
424.9M
115.5M
IPO Year
1992
N/A

Fundamental Metrics

Financial Performance
Metric
KOPN
ACOG
Price
$2.73
$6.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$4.25
$18.00
AVG Volume (30 Days)
3.1M
92.4K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$45,602,295.00
$7,427,199.00
Revenue This Year
N/A
N/A
Revenue Next Year
$43.37
$132.35
P/E Ratio
N/A
N/A
Revenue Growth
3.02
N/A
52 Week Low
$0.71
$3.75
52 Week High
$4.16
$11.54

Technical Indicators

Market Signals
Indicator
KOPN
ACOG
Relative Strength Index (RSI) 58.10 53.56
Support Level $2.28 $5.61
Resistance Level $2.44 $6.91
Average True Range (ATR) 0.15 0.51
MACD 0.04 0.08
Stochastic Oscillator 98.91 66.61

Price Performance

Historical Comparison
KOPN
ACOG

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: